HPV vaccine – New research in The Lancet finds early HPV vaccination in young women effectively reduces the risk of dying from cervical cancer before age 30 to zero. The study, funded by Cancer Research UK, also estimates hundreds of deaths prevented in England to date and
By the time a woman approaches her 30th birthday, the danger she was vaccinated against should no longer be waiting for her.
New research published in The Lancet suggests that for young women who receive the HPV vaccine in their early teen years. the risk of dying from cervical cancer before turning 30 is effectively reduced to zero. It’s a striking claim built on one question scientists hadn’t fully answered before: not just whether the vaccine prevents most cases. but how deeply it can protect people’s lives.
The vaccine was already known to prevent around 90% of cervical cancer cases. This study is the first to focus on mortality rates, and it finds that protection holds at the most consequential point—death—rather than stopping at disease prevention.
The analysis, funded by Cancer Research UK, ties that lifesaving impact to real numbers. In England, roughly 200 cervical cancer deaths have been prevented to date. The study frames those figures as part of a much larger global picture. arguing that vaccination programs are already saving lives at a scale that grows as vaccinated generations age.
Cervical cancer doesn’t appear overnight. HPV—human papillomavirus. a common sexually-transmitted infection spread through skin to skin contact—can usually be cleared by the immune system. But in some people. HPV can lead to abnormal cell growth. which can develop into multiple forms of cancer years later.
That long timeline is exactly why the World Health Organization’s push matters. The WHO aims to eliminate cervical cancer worldwide by urging all of its member countries to vaccinate 90% of girls by age 15. If those goals are met, the researchers estimate that 62 million deaths from cervical cancer could be prevented by the year 2120.
In the paper, the findings are used to argue that the WHO’s targets are within reach—while also urging more focus on boosting vaccine uptake among young people around the world.
Cervical cancer remains a heavy burden. Globally, it is the fourth most common cancer diagnosed in women, with an estimated 660,000 new cases each year. In 2022. 94% of the 350. 000 deaths from cervical cancer occurred in low and middle income countries. particularly in Central America. Southeast Asia and sub-Saharan Africa.
Professor Peter Sasieni. the publication’s lead researcher. captured the stakes in plain terms: “As vaccinated generations grow older. we’ll see many more lives saved from cervical cancer. ” he said. “It is incredible to think that a single jab can almost eliminate a particular type of cancer. and this new research shows just how vital it is to keep HPV vaccination levels high so more people are protected.”.
The protection is powerful, but it’s not absolute—and that distinction matters.
People who have received the HPV vaccine are still encouraged to opt into cervical cancer screenings because the vaccine doesn’t protect against every high-risk strain of HPV. The study’s message, in other words, isn’t vaccination instead of screening. It is vaccination plus routine screenings as the most robust prevention.
The vaccine’s reach goes beyond cervical cancer and goes beyond women. The infection is associated with several cancers. and vaccination can lower the risk for cancers of the mouth and throat. vaginal cancer. vulvar cancer. anal cancer. and penile cancer. The vaccine works best when administered between age 9 and 12. but older teens and people in their 20s are also encouraged to get vaccinated—including men.
Yet even with overwhelmingly positive evidence, HPV vaccination rates have slipped in some places since the pandemic. In the U.S. adoption rates for young people between ages 13 and 17 peaked in 2021 before ticking down afterward. a troubling development in an era where vaccine hesitancy has become woven into public health policy.
HPV vaccine cervical cancer deaths The Lancet Cancer Research UK World Health Organization mortality rates vaccine uptake cervical cancer screening vaccine hesitancy England 200 deaths prevented